- Home
- INCY vs SUI Comparison
INCY vs SUI Comparison
Compare INCY & SUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | SUI |
|---|---|---|
| Founded | 1991 | 1975 |
| Country | United States | United States |
| Employees | N/A | 3614 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 13.9B |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | INCY | SUI |
|---|---|---|
| Price | $127.29 | $113.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 14 |
| Target Price | $103.52 | ★ $141.21 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 04-28-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 3.54% |
| EPS Growth | ★ 4173.33 | 1426.76 |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $3,394,635,000.00 | $2,306,100,000.00 |
| Revenue This Year | $10.44 | $5.24 |
| Revenue Next Year | $10.99 | $5.08 |
| P/E Ratio | $84.80 | ★ N/A |
| Revenue Growth | ★ 13.67 | N/A |
| 52 Week Low | $81.09 | $113.18 |
| 52 Week High | $132.60 | $137.85 |
Technical Indicators
Market Signals| Indicator | INCY | SUI |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 35.84 |
| Support Level | $120.79 | N/A |
| Resistance Level | $131.13 | $125.16 |
| Average True Range (ATR) | 3.01 | 2.04 |
| MACD | -0.27 | -0.45 |
| Stochastic Oscillator | 46.76 | 8.92 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing and recreational vehicle communities. The company currently owns a portfolio of 455 properties, which includes 295 manufactured housing communities and 160 RV communities. Sun targets owning properties that are desirable as second homes or vacation properties, with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.